In December 2022, the Dexcom G7 continuous glucose monitor system was cleared by the FDA for use in people age 2 and older with all diabetes mellitus types. The G7 system is expected to be launched in the United States in early 2023. New features of the Dexcom G7 system include a faster warm-up period of 30 minutes, a 12-hour grace period to replace finished sensors, a 60% smaller footprint than the Dexcom G6, and a redesigned and simplified mobile app. The sensor and transmitter are now integrated into a single disposable unit to be worn for up to 10 days at a time. The G7 system is indicated for wear on the back of the upper arm for patients ages two and older and the upper buttocks for patients ages 2-17 years. The G7 system is not yet integrated with current hybrid closed-loop automated insulin delivery systems that utilize Dexcom G6 (Tandem Control-IQ, Tandem Basal-IQ and Omnipod 5); it is anticipated that Dexcom G7 will be cleared for use with these systems within the next 6 months.
Prepared on behalf of the PES Drug & Therapeutics committee by Patrick Hanley, MD, MSHQS
Last updated: 12/20/22